MOLN
Molecular PartnersMOLN
MOLN
About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Employees: 159
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more funds holding
Funds holding: 5 [Q4 2024] → 6 (+1) [Q1 2025]
0.01% less ownership
Funds ownership: 8.88% [Q4 2024] → 8.87% (-0.01%) [Q1 2025]
17% less capital invested
Capital invested by funds: $17M [Q4 2024] → $14.2M (-$2.88M) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for MOLN.
Financial journalist opinion
Based on 3 articles about MOLN published over the past 30 days
Negative
Reuters
5 days ago
Molecular Partners to cut workforce by a quarter
Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets.
Neutral
GlobeNewsWire
5 days ago
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announces that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a result of this review the Company has informed the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 40 positions, representing a potential of ~24% of all positions.
Neutral
GlobeNewsWire
3 weeks ago
Molecular Partners to Present at Upcoming Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.
Neutral
GlobeNewsWire
1 month ago
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of three posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago, IL. The first poster includes positive Investigational New Drug (IND)-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb for small cell lung cancer patients. The second poster presents initial preclinical data on the second 212Pb-based Radio-DARPin, targeting mesothelin (MSLN) in solid tumors – both programs are co-developed with Orano Med. The third poster includes additional preclinical proof-of-concept data on the logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors.
Neutral
GlobeNewsWire
1 month ago
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority.
Neutral
Zacks Investment Research
2 months ago
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
2 months ago
Molecular Partners to hold three poster presentations at AACR 2025
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer
Neutral
GlobeNewsWire
2 months ago
Molecular Partners Publishes Invitation to Annual General Meeting 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2025.
Neutral
Seeking Alpha
3 months ago
Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
Molecular Partners AG (NASDAQ:MOLN ) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe Legenne - Chief Medical Officer Robert Hendriks - SVP Finance Seth Lewis - SVP Investor Relations, Communications and Strategy Conference Call Participants Jonathan Chang - Leerink Partners Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Joris Zimmermann - Octavian Operator Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only mode.
Neutral
GlobeNewsWire
3 months ago
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its corporate highlights and audited financial results for the full year 2024, as well as the publication of its 2024 Annual Report.
Charts implemented using Lightweight Charts™